Complexity Has Benefits: Data Show Biologics, Targeted Agents Have Better Approval Prospects
Executive Summary
Biologics have 9.1% likelihood of making it through the clinic to approval, compared to 5.7% for new molecular entities, according to an analysis of 10 years of Biomedtracker drug development data by BIO, Informa Pharma Intelligence and QLS.
You may also be interested in...
Vanda Is 1-1 In Fights With FDA As Court Grants Its FOIA Request For Review Documents
Court finds the agency and public would not be harmed if FDA turns over its clinical and statistical reviews of Vanda’s application for Hetlioz jet lag indication. Battles continue over FDA approval of generic Hetlioz and agency’s proposal to refuse the jet lag sNDA.
Biomarkers Improve Odds Of Approval, BIO Study Finds
BIO/Biomedtracker analysis strengthens the case for expanded use of drug development tools like biomarkers with finding that well-defined patient populations in clinical trials are associated with greater likelihood of approval.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.